NZ589445A - Rasagiline for parkinson's disease modification - Google Patents

Rasagiline for parkinson's disease modification

Info

Publication number
NZ589445A
NZ589445A NZ589445A NZ58944509A NZ589445A NZ 589445 A NZ589445 A NZ 589445A NZ 589445 A NZ589445 A NZ 589445A NZ 58944509 A NZ58944509 A NZ 58944509A NZ 589445 A NZ589445 A NZ 589445A
Authority
NZ
New Zealand
Prior art keywords
rasagiline
parkinson
disease modification
disease
modification
Prior art date
Application number
NZ589445A
Other languages
English (en)
Inventor
Ruth Levy
Eli Eyal
Tamar Goren
Sheila Oren
Naim Sayag
Yonatan Weiss
Miri Ben-Ami
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NZ589445A publication Critical patent/NZ589445A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ589445A 2008-06-13 2009-06-12 Rasagiline for parkinson's disease modification NZ589445A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13193608P 2008-06-13 2008-06-13
US18972408P 2008-08-22 2008-08-22
PCT/US2009/003528 WO2009151625A1 (en) 2008-06-13 2009-06-12 Rasagiline for parkinson's disease modification

Publications (1)

Publication Number Publication Date
NZ589445A true NZ589445A (en) 2013-06-28

Family

ID=41415378

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ589445A NZ589445A (en) 2008-06-13 2009-06-12 Rasagiline for parkinson's disease modification

Country Status (13)

Country Link
US (2) US20090312436A1 (https=)
EP (2) EP2296462A4 (https=)
JP (3) JP2011522892A (https=)
CN (2) CN103893160A (https=)
AU (2) AU2009258151A1 (https=)
BR (1) BRPI0909894A2 (https=)
CA (1) CA2727022A1 (https=)
EA (1) EA201170018A1 (https=)
IL (1) IL209131A0 (https=)
MX (1) MX2010013766A (https=)
NZ (1) NZ589445A (https=)
WO (1) WO2009151625A1 (https=)
ZA (1) ZA201008484B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (ja) * 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
SG189454A1 (en) * 2010-10-26 2013-05-31 Teva Pharma Deuterium enriched rasagiline
CA2732440C (en) * 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
AU2012323346A1 (en) * 2011-10-10 2014-05-15 Teva Pharmaceutical Industries Ltd Rasagiline citramide
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
US20150275302A1 (en) * 2014-04-01 2015-10-01 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for rasagiline
EP3432931A1 (en) * 2016-03-26 2019-01-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositons for n-propargylamine derivative
CN110831606A (zh) * 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
EP3917508A4 (en) * 2019-01-28 2022-12-21 Mitochondria Emotion, Inc. EAAT2 ACTIVATORS AND METHODS OF USE THEREOF
GB202109826D0 (en) * 2021-07-07 2021-08-18 Bial Portela & Ca Sa Treatment regimens for early idiopathic parkinson's disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CN1031995C (zh) * 1991-01-02 1996-06-12 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体的制法
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ES2241064T3 (es) * 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
EP1418834A4 (en) * 2001-07-20 2007-04-04 Sinai School Medicine METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE
KR20060005009A (ko) * 2001-12-28 2006-01-16 다케다 야쿠힌 고교 가부시키가이샤 배뇨 장애 예방제/치료제
ES2432117T3 (es) * 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
WO2006091657A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2630037C (en) * 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101600346B (zh) * 2006-12-14 2013-08-21 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
CN101557706B (zh) 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090143388A1 (en) * 2007-08-29 2009-06-04 Mohanakumar Kochupurackal Para Treatment of brain disorders
CA2698695A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
BRPI0909997A2 (pt) * 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan

Also Published As

Publication number Publication date
CA2727022A1 (en) 2009-12-17
WO2009151625A1 (en) 2009-12-17
EP2666356A1 (en) 2013-11-27
MX2010013766A (es) 2011-03-15
EP2296462A1 (en) 2011-03-23
AU2009258151A1 (en) 2009-12-17
BRPI0909894A2 (pt) 2015-07-28
US20140243418A1 (en) 2014-08-28
IL209131A0 (en) 2011-01-31
JP2015096532A (ja) 2015-05-21
ZA201008484B (en) 2012-05-30
EP2296462A4 (en) 2011-06-15
CN102065687A (zh) 2011-05-18
JP2017081938A (ja) 2017-05-18
AU2016259315A1 (en) 2016-12-01
US20090312436A1 (en) 2009-12-17
JP2011522892A (ja) 2011-08-04
CN103893160A (zh) 2014-07-02
EA201170018A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
NZ589445A (en) Rasagiline for parkinson's disease modification
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
NZ714963A (en) Compositions and methods for treating anemia
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2007145863A3 (en) Sustained release formulation of naltrexone
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MX2009005503A (es) Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea.
NZ597675A (en) Medicament for the long term nsaid use
RU2008107113A (ru) Средство и способ профилактики и лечения пациентов с болезнью альцгеймера
NZ599227A (en) Therapeutic agent for chronic pain

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 JUN 2016 BY DENNEMEYER SA

Effective date: 20131115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 JUN 2019 BY DENNEMEYER + CO

Effective date: 20140828

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 12 JUN 2029 BY DENNEMEYER + CO

Effective date: 20140828

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 JUN 2022 BY DENNEMEYER + CO

Effective date: 20140828